Atherosclerotic cardiovascular disease (ASCVD) involves the buildup of cholesterol plaque in arteries and includes acute coronary syndrome, peripheral arterial disease, and events such as myocardial infarction and stroke. ASCVD is a major cause of morbidity and mortality in the United States. Risk factors such as dyslipidemia, diabetes mellitus (DM), obesity, inactive lifestyle, hypertension, smoking, and family history inform ASCVD risk assessments. Understanding a patient’s 10-year ASCVD risk is fundamental in establishing appropriate medical management (eg, cholesterol-lowering medication). Traditional lipid tests for markers such as total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides are recommended for the evaluation of ASCVD risk; such testing is also used for screening and monitoring. Nontraditional, novel markers like apolipoproteins, lipoprotein particles, and high-sensitivity C-reactive protein (hsCRP) are gaining recognition for their role in the evaluation of high-risk patients.
Quick Answers for Clinicians
Traditional markers of atherosclerotic cardiovascular disease (ASCVD) are those included in a lipid panel: total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. There are generally well-established guidelines for use of these markers in ASCVD risk determination. Newer, nontraditional disease markers include apolipoproteins, high-sensitivity C-reactive protein (hsCRP), lipoprotein(a), and lipoprotein particles. Genotyping is also considered a nontraditional method in ASCVD risk evaluation. These markers and methods are not yet universally accepted for risk evaluation in the general population. However, they may be useful in assessment and risk stratification, especially for high-risk individuals.
Although research is ongoing, there is insufficient evidence to recommend or discourage the use of certain nontraditional markers (eg, high-sensitivity C-reactive protein [hsCRP]) in asymptomatic adults. However, the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines support the use of apolipoprotein B (apoB), hsCRP, and low-density lipoprotein (LDL) particle concentration to guide effective therapy and decision-making. Nontraditional markers may be beneficial, especially for select, higher-risk groups.
General population screening for dyslipidemia can begin for individuals at 20 years of age. However, because the U.S. Preventive Services Task Force (USPSTF) found insufficient evidence to support screening for individuals 20-39 years, clinicians should use clinical judgment for this age group. Individuals with type 1 or type 2 diabetes mellitus (DM) should be screened. See Screening for age-related frequency recommendations.
Statin treatment is recommended for individuals :
- With clinical atherosclerotic cardiovascular disease (ASCVD)
- With primary low-density lipoprotein cholesterol (LDL-C) levels ≥190 mg/dL
- 40-75 years of age with diabetes mellitus (DM) and an LDL-C measurement of 70-189 mg/dL, without clinical ASCVD
- 40-75 years of age and without clinical ASCVD or DM but with an LDL-C measurement of 70-189 mg/dL and an estimated 10-year ASCVD risk ≥7.5% (clinician-patient discussion is required for this population)
Risk Assessment
Several tools have been developed to determine a patient’s 10-year risk of an ASCVD event. These calculators should be used to establish appropriate treatment.
The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend incorporating the Pooled Cohort Equations into clinical practice. This calculator is specific to age and sex and helps predict 10-year and lifetime risks for hard ASCVD in patients with or without DM. The risk percentage helps determine the need for and intensity of treatment. Treatment is then focused on reducing the risk rather than on treating cholesterol levels.
The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines recommend using at least one of the following four risk calculators for dyslipidemia screening:
- The Framingham Risk Score (Adult Treatment Panel III [ATP-III]) is an algorithm to help predict risk specifically for coronary heart disease (CHD), specifically, in a White population and tends to be more accurate for women.
- The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of risk factors that predicts progression to clinically overt CVD or progression of subclinical disease; it is more appropriate for patients 45-85 years of age and of select racial/ethnic groups.
- The Reynolds Risk Score is a risk calculator that includes hsCRP results and family history of premature ASCVD, in addition to other factors.
- The United Kingdom Prospective Diabetes Study (UKPDS) risk engine calculates ASCVD risk specifically in individuals with type 2 DM.
Laboratory Testing
Traditional Risk Markers
Traditional risk markers are often assessed usinga lipid panel. Fasting measurements of total cholesterol, LDL-C, HDL-C, and triglycerides provides the most precise lipid assessment. Nonfasting measurements can be used if fasting is impractical.
Total Cholesterol
A total cholesterol test provides one measurement for the total amount of cholesterol in the blood, whether it be LDL-C, HDL-C, or triglycerides.
Low-Density Lipoprotein Cholesterol
An LDL-C level can be derived using an equation with other lipid measurements, but an LDL-C measurement should be obtained directly in patients with DM, known vascular disease, or a fasting triglyceride level >250 mg/dL.
High-Density Lipoprotein Cholesterol
HDL-C measurements should be part of dyslipidemia screening tests. Non-HDL-C measurements can be derived by subtracting HDL-C from total cholesterol. A non-HDL-C level is helpful in determining risk in patients with DM, established ASCVD, or elevated triglycerides; it can also provide information on a patient’s total atherogenic lipoprotein burden.
Triglycerides
Triglyceride testing can help identify patients with insulin resistance syndrome or those at increased risk for ASCVD; it should be included in routine screening.
Nontraditional Risk Markers
Apolipoproteins
In at-risk individuals, apolipoprotein evaluation, namely apoB and the apoB/apoA1 ratio, may be helpful to assess residual risk and guide decision-making. Both measurements are recommended to improve risk prediction ; however, the usefulness of apoB in assessing risk for a first ASCVD event is uncertain. ApoB measurements that reflect LDL particle concentration and other atherogenic lipoprotein levels may be useful for determining therapy success. Evidence is insufficient to conclude that the apoA1 marker improves risk prediction for cardiovascular events in at-risk populations.
High-Sensitivity C-Reactive Protein
An hsCRP measurement can help stratify risk in individuals with a borderline risk assessment or with intermediate or high risk and an LDL-C measurement of <130 mg/dL. The U.S. Preventive Services Task Force (USPSTF) determined that there is insufficient evidence to recommend or discourage hsCRP measurement as part of the risk assessment for ASCVD in asymptomatic adults. An hsCRP test should not be performed in patients with current acute illness.
Lipoprotein(a)
Although there is no justification for screening the general population for lipoprotein(a) [Lp(a)] concentration, Lp(a) testing may be considered for patients with a family history of early ASCVD or to refine the evaluation of patients at moderate risk; high concentrations may support more aggressive control of other lipoprotein factors.
Lipoprotein Particle Count
Lipoprotein particle number evaluation (eg, with the LipoFit test) may be appropriate for high-risk patients, such as those with type 2 DM, to guide and refine therapy; it is not recommended for routine CVD risk assessment in most individuals.
Lipoprotein-Associated Phospholipase A2
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an indicator specifically of vascular inflammation, independent of obesity. Measurements can provide additional information for risk stratification and can be especially useful in the presence of hsCRP elevations. Studies have shown that Lp-PLA2 has greater specificity than hsCRP. Individuals with elevated Lp-PLA2 and hsCRP are at substantial risk, even with low or moderately elevated LDL-C.
Genotyping
The apolipoprotein E (APOE) gene is associated with modulation of the plasma lipids profile. APOE genotyping can provide supporting evidence for a diagnosis of premature coronary heart disease; it can also be used to screen individuals with a family history of type III hyperlipoproteinemia. It should be used for CVD risk assessment only and has variable significance in prediction.
Evaluation for variants in the LDLR, APOB, PCSK9, or LDLRAP1 genes may be appropriate for individuals with familial hypercholesterolemia to identify the genetic cause. For more information, see the Familial Hypercholesterolemia Test Fact Sheet.
Screening
The AACE/ACE has issued the following screening recommendations :
- Individuals with a family history of premature ASCVD or high cholesterol levels should be screened for familial hypercholesterolemia.
- Children at risk for familial hypercholesterolemia should be screened for dyslipidemia at 3 years, between 9 and 11 years, and at 18 years.
- Adolescents older than 16 years who have ASCVD risk factors, are overweight or obese, or have other symptoms of insulin resistance should be screened for dyslipidemia every 5 years or more frequently.
- Adults with type 1 or type 2 DM should be screened annually for dyslipidemia.
- Men 20-45 years or women 20-55 years without ASCVD risk factors should be screened for dyslipidemia every 5 years.
- Men 45-65 years and women 55-65 years without ASCVD risk factors should be screened for dyslipidemia at least every 1-2 years. Clinical judgment should be used to modify testing intervals as appropriate.
- Adults older than 65 years with one or no risk factor should be screened for dyslipidemia annually; those with two or more ASCVD risk factors should have a lipid assessment performed.
The USPSTF found insufficient evidence to recommend or discourage screening for dyslipidemia in adults 20-39 years or in children and adolescents; clinicians should use their judgment.
Nontraditional markers are not recommended for routine screening or risk assessment in asymptomatic adults, and routine testing of children for nontraditional risk factors/biomarkers is also not recommended, due to a lack of convincing data.
Additionally, patients on statin therapy should be screened for new-onset DM according to current DM guidelines.
Monitoring
Lipid testing is recommended to assess medication and lifestyle adherence. A baseline fasting lipid panel should be repeated 1-3 months after statin initiation, after which monitoring with a lipid panel should be performed every 3-12 months. The ACC/AHA guideline de-emphasizes fixed goals for LDL and HDL and instead supports a percentage decrease in LDL-C of 30-49% for moderate-intensity therapy and >50% for high-intensity therapy. AACE/ACE guidelines recommend treating to achieve lipid targets based on risk category. The LDL-C targets for specific populations are as follow :
- Low-risk patients: <130 mg/dL
- High-risk patients: <100 mg/dL
- Very high-risk patients: <70 mg/dL
- Extreme-risk patients: <55 mg/dL
ARUP Laboratory Tests
Use to assess CVD risk and guide therapy
Quantitative Enzymatic Assay
Quantitative Spectrophotometry/Quantitative Enzymatic Assay
Use to assess CVD risk and guide therapy
Quantitative Enzymatic Assay
Quantitative Detergent Solubilization/ Enzymatic Assay
Detergent Solubilization/Enzymatic Assay
Quantitative Enzymatic Assay
Acceptable secondary CVD risk screen for specific populations
Quantitative Immunoturbidimetry
Quantitative Immunoturbidimetry
Not recommended for ASCVD risk assessment
Use to detect Tangier disease
Quantitative Immunoturbidimetry
May aid in ASCVD risk stratification in specific populations
Not recommended for ASCVD risk assessment in asymptomatic adults
Quantitative Immunoturbidimetry
May aid in ASCVD risk stratification in specific populations
Not recommended for ASCVD risk assessment in asymptomatic adults
Quantitative Immunoturbidimetry
Appropriate for high-risk patients to guide therapy
Quantitative Nuclear Magnetic Resonance Spectroscopy/ Quantitative Enzymatic Assay/Detergent Solubilization
Not recommended for CVD risk assessment in most individuals
Quantitative Nuclear Magnetic Resonance Spectroscopy
May aid in ASCVD risk stratification, especially in individuals with elevated hsCRP
Quantitative Enzymatic Assay/Spectrophotometry
Use to confirm diagnosis of familial hypercholesterolemia
Massively Parallel Sequencing
Use to provide supporting evidence for a diagnosis of type III hyperlipoproteinemia for evaluation of premature coronary heart disease
Polymerase Chain Reaction/Fluorescence Monitoring
References
-
29998297
U.S. Preventive Services Task Force, Curry SJ, Krist AH, et al. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(3):272-280.
-
28437620
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1-87.
-
27838723
U.S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997-2007.
-
24239923
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
-
24222018
Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-S73.
-
AHA/ACC - ASCVD Risk Calculator
American Heart Association. 2018 prevention guidelines tool CV risk calculator. [Accessed: Aug 2020]
-
MDCalc - Framingham Coronary Heart Disease Risk Score
MDCalc. Framingham risk score for hard coronary heart disease. [Accessed: Aug 2020]
-
MESA 10-Year CHD Risk with Coronary Artery Calcification
Multi-Ethnic Study of Atherosclerosis. MESA 10-year CHD risk with coronary artery calcification. [Accessed: Aug 2020]
-
Reynolds risk score for cardiovascular risk in women
MCCalc. Reynolds risk score for cardiovascular risk in women. [Accessed: Sep 2020]
-
UKPDS Risk Engine
UKPDS risk engine. University of Oxford. [Accessed: Aug 2020]
-
27840858
Sandhu PK, Musaad SMA, Remaley AT, et al. Lipoprotein biomarkers and risk of cardiovascular disease: a laboratory medicine best practices (LMBP) systematic review. J Appl Lab Med. 2016;1(2):214-229.
-
27222591
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381.
-
21555711
Balagopal PB, de Ferranti SD, Cook S, et al. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. Circulation. 2011;123(23):2749-2769.
28460374
Allaire J, Vors C, Couture P, et al. LDL particle number and size and cardiovascular risk: anything new under the sun? Curr Opin Lipidol. 2017;28(3):261-266.
26800892
El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease [published correction appears in Cardiovasc Diabetol. 2016;15:35]. Cardiovasc Diabetol. 2016;15:12.
26224808
Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. Circulation. 2015;132(10):916-922.
Medical Experts
Genzen

Components: APOB, LDLR, LDLRAP1, PCSK9